Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations

Affiliations

• ¹ Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan. isao-miyazaki@taiho.co.jp.
• ² Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ³ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ⁴ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
• ⁵ Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan.
• ⁶ Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
• ⁷ Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
• ⁸ Northwell Health Cancer Institute, Lenox Hill Hospital, New York, NY, USA.
• ⁹ Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ¹⁰ Department of Education and Support for Regional Medicine, Tohoku University Hospital, Sendai, Japan.
• ¹¹ Helsinn Healthcare SA, Lugano, Switzerland.
• ¹² Dana Cancer Center, Toledo, OH, USA.
• ¹³ Department of Pediatrics, Oregon Health Sciences University, Portland, OR, USA.
• ¹⁴ Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org.
• ¹⁵ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. somwarr@mskcc.org.